As an academic clinician, I have developed expertise in Pediatric Renal Tumors, have regional and national leadership roles, and a strong international reputation in clinical expertise. I am the Program Leader and Institutional Disease Expert for Renal Tumors at DFCI/BCH. In this capacity, I am involved in the care and treatment plans for all patients with Renal Tumors seen at our program. I am a member of the COG Renal Tumors Steering Committee and am Chair of the Renal Tumors Biology and Classification Study, as well as the Vice-Chair for the protocol for Treatment of Very Low Risk and Standard Risk Wilms Tumor. I have responsibility for real time central review of central radiology, pathology and surgical reports of all renal tumor patients nationally (over 600 patients a year) and assignment of appropriate risk stratification to allow enrollment on appropriate therapeutic studies, a large national study which has enrolled almost 6000 patients since 2006. My interest in the improvement of outcomes in pediatric renal tumor patients has lead a study of urine proteomics to identify urinary markers of high risk renal disease. I currently chair the COG working group for the development of the next therapeutic study for patients with Favorable Histology Wilms Tumor, which will aim to incorporate additional biologic markers in risk stratification.